Clinical Outcomes of Switching From Warfarin to Apixaban or Rivaroxaban in Patients With Atrial Fibrillation: A Nationwide Multidatabase Study
Circulation: Cardiovascular Quality and Outcomes · 2025
DOI: 10.1161/circoutcomes.124.011890 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Circulation: Cardiovascular Quality and Outcomes, 2025. Verfasst von Dae Hyun Kim und 6 weiteren Autor:innen. Beteiligte Einrichtung: Harvard Medical School, Boston, MA (D.H.K., D.K., D.E.S., K.J.L.). Hauptthemen laut MEDLINE: Atrial Fibrillation, Drug Substitution, Factor Xa Inhibitors, Ischemic Stroke. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS.
Abstract (Originalsprache)
BACKGROUND: The benefits of switching from warfarin to direct oral anticoagulants in atrial fibrillation remain unclear. METHODS: This retrospective study used the Medicare fee-for-service (2013–2020) and Optum Deidentified Clinformatics Data Mart databases (2013–2023). Among patients with atrial fibrillation who received warfarin for at least 180 days, we created 2 cohorts: (1) patients switching to apixaban versus continuing warfarin (the apixaban cohort) and (2) patients switching to rivaroxaban versus continuing warfarin (the rivaroxaban cohort). The index date was the switch date for switchers and a matched date based on warfarin duration for warfarin continuers. After 1:1 propensity score matching, we estimated the rate ratios (RR) for a composite of ischemic stroke, major bleeding, and death in each database and pooled the results using meta-analysis. Subgroup analyses by claims-based frailty and by follow-up time (first 60 days versus beyond 60 days) were performed. RESULTS: In the apixaban cohort (n=164 480; mean age, 80.5 years; 55.5% female; median follow-up, 354 days), switching to apixaban was associated with a lower rate of composite outcome (97.1 versus 104.9 per 1000 person-years; rate ratio, 0.92 [95% CI, 0.89–0.95]) compared with continuing warfarin. In the rivaroxaban cohort (n=96 030, mean age 79.7 years, 54.8% female, median follow-up 365 days), switching to rivaroxaban was associated with an increased rate of composite outcome (105.8 versus 99.3 per 1000 person-years; rate ratio, 1.08 [95% CI, 1.04–1.13]). No heterogeneity by frailty levels was observed. However, switching was associated with an initial risk increase within the first 60 days, followed by risk attenuation beyond 60 days, for both apixaban and rivaroxaban. CONCLUSIONS: In patients with atrial fibrillation on warfarin therapy, switching to apixaban may reduce the risk of ischemic stroke, major bleeding, and death, whereas switching to rivaroxaban may increase the risk. For both apixaban and rivaroxaban, switching may temporarily increase risk during the first 60 days.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Harvard Medical School, Boston, MA (D.H.K., D.K., D.E.S., K.J.L.).
- Hinda and Arthur Marcus Institute for Aging Research, Hebrew SeniorLife, Boston, MA (D.H.K., D.K.).
- Division of Gerontology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA (D.H.K.).
- Section of Cardiovascular Medicine, Department of Medicine, Boston Medical Center, MA (D.K.).
- Division of General Internal Medicine, Department of Medicine, Massachusetts General Hospital, Boston (D.E.S., K.J.L.).
- Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, MA (A.C., Y.Z., Q.C., K.J.L.).
ORCID-Profile: Dae Hyun Kim, Darae Ko, Daniel E Singer, Yichi Zhang, Qiaoxi Chen, Kueiyu Joshua Lin
Förderung
- NIA NIH HHS
Zitieren
APA
Kim, D. H., Ko, D., Singer, D. E., Cervone, A., Zhang, Y., Chen, Q., & Lin, K. J. (2025). Clinical Outcomes of Switching From Warfarin to Apixaban or Rivaroxaban in Patients With Atrial Fibrillation: A Nationwide Multidatabase Study. Circulation: Cardiovascular Quality and Outcomes. https://doi.org/10.1161/circoutcomes.124.011890
Vancouver
Kim DH, Ko D, Singer DE, Cervone A, Zhang Y, Chen Q, et al. Clinical Outcomes of Switching From Warfarin to Apixaban or Rivaroxaban in Patients With Atrial Fibrillation: A Nationwide Multidatabase Study. Circulation: Cardiovascular Quality and Outcomes. 2025. doi:10.1161/circoutcomes.124.011890
BibTeX
@article{Kim2025,
author = {Kim, Dae Hyun and Ko, Darae and Singer, Daniel E and Cervone, Alexander and Zhang, Yichi and Chen, Qiaoxi and Lin, Kueiyu Joshua},
title = {Clinical Outcomes of Switching From Warfarin to Apixaban or Rivaroxaban in Patients With Atrial Fibrillation: A Nationwide Multidatabase Study},
journal = {Circulation: Cardiovascular Quality and Outcomes},
year = {2025},
doi = {10.1161/circoutcomes.124.011890}
}
EUVIMED